Discovery of Novel Pyrrolo[2,3-d]pyrimidine-based Derivatives as Potent JAK/HDAC Dual Inhibitors for the Treatment of Refractory Solid Tumors

Potent Dual BET/HDAC Inhibitors for Efficient Treatment of Pancreatic Cancer

(2020) Shipeng He et al.   ANGEWANDTE CHEMIE-INTERNATIONAL EDITION

Dual-Target Inhibitors Based on HDACs: Novel Antitumor Agents for Cancer Therapy

(2020) Tingting Liu et al.   JOURNAL OF MEDICINAL CHEMISTRY

Discovery of Novel Janus Kinase (JAK) and Histone Deacetylase (HDAC) Dual Inhibitors for the Treatment of Hematological Malignancies

(2019) Xuewu Liang et al.   JOURNAL OF MEDICINAL CHEMISTRY

Novel-targeted therapy for hematological malignancies with JAK and HDAC dual inhibitors

(2019) Xuewu Liang et al.   Future Medicinal Chemistry

Discovery of Janus Kinase 2 (JAK2) and Histone Deacetylase (HDAC) Dual Inhibitors as a Novel Strategy for the Combinational Treatment of Leukemia and Invasive Fungal Infections

(2018) Yahui Huang et al.   JOURNAL OF MEDICINAL CHEMISTRY

Discovery of Novel Pazopanib-Based HDAC and VEGFR Dual Inhibitors Targeting Cancer Epigenetics and Angiogenesis Simultaneously

(2018) Jie Zang et al.   JOURNAL OF MEDICINAL CHEMISTRY

Chimeric HDAC inhibitors: Comprehensive review on the HDAC-based strategies developed to combat cancer

(2018) Heba M. Hesham et al.   MEDICINAL RESEARCH REVIEWS

Design and synthesis of potent dual inhibitors of JAK2 and HDAC based on fusing the pharmacophores of XL019 and vorinostat

(2018) Yu-yi Chu-Farseeva et al.   EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

HDAC Inhibition Counteracts Metastatic Re-Activation of Prostate Cancer Cells Induced by Chronic mTOR Suppression

(2018) Jasmina Makarević et al.   Cells

Design and Synthesis of Ligand Efficient Dual Inhibitors of Janus Kinase (JAK) and Histone Deacetylase (HDAC) Based on Ruxolitinib and Vorinostat

(2017) Lianbin Yao et al.   JOURNAL OF MEDICINAL CHEMISTRY

HDAC inhibition potentiates immunotherapy in triple negative breast cancer

(2017) Manuela Terranova-Barberio et al.   Oncotarget

Feedback Activation of Leukemia Inhibitory Factor Receptor Limits Response to Histone Deacetylase Inhibitors in Breast Cancer

(2016) Hanlin Zeng et al.   CANCER CELL

Polypharmacology in Drug Development: A Minireview of Current Technologies

(2016) Zhi Tan et al.   ChemMedChem

Design, synthesis and biological evaluation of N-phenylquinazolin-4-amine hybrids as dual inhibitors of VEGFR-2 and HDAC

(2016) Fan-Wei Peng et al.   EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

Design and Synthesis of Janus Kinase 2 (JAK2) and Histone Deacetlyase (HDAC) Bispecific Inhibitors Based on Pacritinib and Evidence of Dual Pathway Inhibition in Hematological Cell Lines

(2016) Eugene Guorong Yang et al.   JOURNAL OF MEDICINAL CHEMISTRY

Past, Present, and Future of Targeting Ras for Cancer Therapies

(2016) Zhi Tan et al.   MINI-REVIEWS IN MEDICINAL CHEMISTRY

Discovery and Development of Janus Kinase (JAK) Inhibitors for Inflammatory Diseases

(2014) James D. Clark et al.   JOURNAL OF MEDICINAL CHEMISTRY

Histone deacetylase inhibitors

(2013) Marije Slingerland et al.   ANTI-CANCER DRUGS

Discovery of 1-Methyl-1H-imidazole Derivatives as Potent Jak2 Inhibitors

(2013) Qibin Su et al.   JOURNAL OF MEDICINAL CHEMISTRY

Development of a Chimeric c-Src Kinase and HDAC Inhibitor

(2013) Kristin S. Ko et al.   ACS Medicinal Chemistry Letters

Identification of Imidazo-Pyrrolopyridines as Novel and Potent JAK1 Inhibitors

(2012) Janusz J. Kulagowski et al.   JOURNAL OF MEDICINAL CHEMISTRY

Phase II trial of the histone deacetylase inhibitor romidepsin in patients with recurrent/metastatic head and neck cancer

(2012) Missak Haigentz et al.   ORAL ONCOLOGY

Novel Chimeric Histone Deacetylase Inhibitors: A Series of Lapatinib Hybrides as Potent Inhibitors of Epidermal Growth Factor Receptor (EGFR), Human Epidermal Growth Factor Receptor 2 (HER2), and Histone Deacetylase Activity

(2010) Siavosh Mahboobi et al.   JOURNAL OF MEDICINAL CHEMISTRY

Phase II, two-stage, single-arm trial of the histone deacetylase inhibitor (HDACi) romidepsin in metastatic castration-resistant prostate cancer (CRPC)

(2009) L. R. Molife et al.   ANNALS OF ONCOLOGY